Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@jax.org
Therapy Name | YL201 |
Synonyms | |
Therapy Description |
YL201 is an antibody-drug conjugate (ADC) comprising an antibody that targets an undisclosed tumor-associated antigen (TAA) linked to an undisclosed cytotoxic agent, which potentially leads to killing of tumor cells expressing the TAA (NCI Drug Dictionary). |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
YL201 | YL-201|YL 201 | YL201 is an antibody-drug conjugate (ADC) comprising an antibody that targets an undisclosed tumor-associated antigen (TAA) linked to an undisclosed cytotoxic agent, which potentially leads to killing of tumor cells expressing the TAA (NCI Drug Dictionary). |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT05434234 | Phase I | YL201 | A Study of YL201 in Patients With Advanced Solid Tumors | Recruiting | USA | 1 |